SCHEMBL3014015

SCHEMBL3014015

COc1ccc(Br)cc1S(=O)(=O)C1CCN(c2nc(Cc3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
TP53 P04637 1/20 0.38
P2RX7 Q99572 2/20 0.36
DRD2 P14416 5/20 0.36
DRD4 P21917 5/20 0.36
DRD3 P35462 5/20 0.36
LMNA P02545 3/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 2/20 0.35
PPARG P37231 1/20 0.35
GFER P55789 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ALOX15 P16050 1/20 0.34
AR P10275 1/20 0.34
TSHR P16473 1/20 0.33
ERBB2 P04626 3/20 0.32
EPHA2 P29317 3/20 0.32
KDR P35968 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013140 0.95 DRD2 (0.39) MAPTTP53DRD2DRD4DRD3
SCHEMBL3003617 0.94 GAA (0.37) MAPTTP53DRD2DRD4DRD3
SCHEMBL3018015 0.93 MAPT (0.41) MAPTTP53P2RX7DRD2LMNA
SCHEMBL3011844 0.91 HSD17B10 (0.40) MAPTTP53P2RX7LMNAALDH1A1
SCHEMBL15671702 0.90 MAPT (0.42) MAPTTP53DRD2LMNAALDH1A1
SCHEMBL15671681 0.90 MAPT (0.38) MAPTTP53DRD2DRD4DRD3
SCHEMBL3005352 0.89 SLC6A4 (0.37) MAPTTP53P2RX7DRD2DRD4
SCHEMBL3009617 0.88 GAA (0.36) MAPTTP53DRD2DRD4DRD3
SCHEMBL3002683 0.88 CTSS (0.38) GAASMN1; SMN2
SCHEMBL3006331 0.88 TP53 (0.40) MAPTTP53DRD2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885TP53 2880/4885P2RX7 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.